Enhancing effect of indirubin derivatives on 1,25-dihydroxyvitamin D3- and all-trans retinoic acid-induced differentiation of HL-60 leukemia cells

Seung Hyun Kim, Si Wouk Kim, Soo Jeong Choi, Yong Chul Kim, Tae Sung Kim

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The induction of differentiation represents a new and promising approach to cancer therapy, well illustrated by the treatment of acute promyelocytic leukemia (APL) with 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] or all-trans retinoic acid (ATRA). Using combinations of low, nontoxic concentrations of either 1,25-(OH)2D3 or ATRA and differentiation-enhancing chemicals, adverse effects such as hypercalcemic effects have been ameliorated, and long-term survival has been improved. Indirubin has been demonstrated to exert anti-leukemic effects in cases of chronic myelocytic leukemia. Previously, we synthesized a series of indirubin derivatives and evaluated their anti-proliferative properties against cancer cells. In this study, we determined the enhancing activities of these derivatives on 1,25-(OH)2D3- and ATRA-induced differentiation of human promyelocytic leukemia HL-60 cells. Importantly, some of these derivatives were found to synergistically enhance the differentiation of HL-60 cells in a concentration-dependent manner when coupled with low doses of either 1,25-(OH)2D3 or ATRA. The ability of indirubin derivatives to enhance the differentiation potential of 1,25-(OH)2D3 or ATRA may improve the ultimate outcomes of APL therapy.

Original languageEnglish
Pages (from-to)6752-6758
Number of pages7
JournalBioorganic and Medicinal Chemistry
Volume14
Issue number19
DOIs
Publication statusPublished - 2006 Oct 1

Fingerprint

Calcitriol
HL-60 Cells
Tretinoin
Leukemia
Derivatives
Acute Promyelocytic Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Neoplasms
Cells
indirubin
Survival
Therapeutics

Keywords

  • 1,25-Dihydroxyvitamin D
  • All-trans retinoic acid
  • Differentiation
  • Indirubin
  • Leukemia

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Organic Chemistry
  • Drug Discovery
  • Pharmaceutical Science

Cite this

Enhancing effect of indirubin derivatives on 1,25-dihydroxyvitamin D3- and all-trans retinoic acid-induced differentiation of HL-60 leukemia cells. / Kim, Seung Hyun; Kim, Si Wouk; Choi, Soo Jeong; Kim, Yong Chul; Kim, Tae Sung.

In: Bioorganic and Medicinal Chemistry, Vol. 14, No. 19, 01.10.2006, p. 6752-6758.

Research output: Contribution to journalArticle

@article{1e0bbe505a124ea991bd6a978665d594,
title = "Enhancing effect of indirubin derivatives on 1,25-dihydroxyvitamin D3- and all-trans retinoic acid-induced differentiation of HL-60 leukemia cells",
abstract = "The induction of differentiation represents a new and promising approach to cancer therapy, well illustrated by the treatment of acute promyelocytic leukemia (APL) with 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] or all-trans retinoic acid (ATRA). Using combinations of low, nontoxic concentrations of either 1,25-(OH)2D3 or ATRA and differentiation-enhancing chemicals, adverse effects such as hypercalcemic effects have been ameliorated, and long-term survival has been improved. Indirubin has been demonstrated to exert anti-leukemic effects in cases of chronic myelocytic leukemia. Previously, we synthesized a series of indirubin derivatives and evaluated their anti-proliferative properties against cancer cells. In this study, we determined the enhancing activities of these derivatives on 1,25-(OH)2D3- and ATRA-induced differentiation of human promyelocytic leukemia HL-60 cells. Importantly, some of these derivatives were found to synergistically enhance the differentiation of HL-60 cells in a concentration-dependent manner when coupled with low doses of either 1,25-(OH)2D3 or ATRA. The ability of indirubin derivatives to enhance the differentiation potential of 1,25-(OH)2D3 or ATRA may improve the ultimate outcomes of APL therapy.",
keywords = "1,25-Dihydroxyvitamin D, All-trans retinoic acid, Differentiation, Indirubin, Leukemia",
author = "Kim, {Seung Hyun} and Kim, {Si Wouk} and Choi, {Soo Jeong} and Kim, {Yong Chul} and Kim, {Tae Sung}",
year = "2006",
month = "10",
day = "1",
doi = "10.1016/j.bmc.2006.05.044",
language = "English",
volume = "14",
pages = "6752--6758",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "19",

}

TY - JOUR

T1 - Enhancing effect of indirubin derivatives on 1,25-dihydroxyvitamin D3- and all-trans retinoic acid-induced differentiation of HL-60 leukemia cells

AU - Kim, Seung Hyun

AU - Kim, Si Wouk

AU - Choi, Soo Jeong

AU - Kim, Yong Chul

AU - Kim, Tae Sung

PY - 2006/10/1

Y1 - 2006/10/1

N2 - The induction of differentiation represents a new and promising approach to cancer therapy, well illustrated by the treatment of acute promyelocytic leukemia (APL) with 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] or all-trans retinoic acid (ATRA). Using combinations of low, nontoxic concentrations of either 1,25-(OH)2D3 or ATRA and differentiation-enhancing chemicals, adverse effects such as hypercalcemic effects have been ameliorated, and long-term survival has been improved. Indirubin has been demonstrated to exert anti-leukemic effects in cases of chronic myelocytic leukemia. Previously, we synthesized a series of indirubin derivatives and evaluated their anti-proliferative properties against cancer cells. In this study, we determined the enhancing activities of these derivatives on 1,25-(OH)2D3- and ATRA-induced differentiation of human promyelocytic leukemia HL-60 cells. Importantly, some of these derivatives were found to synergistically enhance the differentiation of HL-60 cells in a concentration-dependent manner when coupled with low doses of either 1,25-(OH)2D3 or ATRA. The ability of indirubin derivatives to enhance the differentiation potential of 1,25-(OH)2D3 or ATRA may improve the ultimate outcomes of APL therapy.

AB - The induction of differentiation represents a new and promising approach to cancer therapy, well illustrated by the treatment of acute promyelocytic leukemia (APL) with 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] or all-trans retinoic acid (ATRA). Using combinations of low, nontoxic concentrations of either 1,25-(OH)2D3 or ATRA and differentiation-enhancing chemicals, adverse effects such as hypercalcemic effects have been ameliorated, and long-term survival has been improved. Indirubin has been demonstrated to exert anti-leukemic effects in cases of chronic myelocytic leukemia. Previously, we synthesized a series of indirubin derivatives and evaluated their anti-proliferative properties against cancer cells. In this study, we determined the enhancing activities of these derivatives on 1,25-(OH)2D3- and ATRA-induced differentiation of human promyelocytic leukemia HL-60 cells. Importantly, some of these derivatives were found to synergistically enhance the differentiation of HL-60 cells in a concentration-dependent manner when coupled with low doses of either 1,25-(OH)2D3 or ATRA. The ability of indirubin derivatives to enhance the differentiation potential of 1,25-(OH)2D3 or ATRA may improve the ultimate outcomes of APL therapy.

KW - 1,25-Dihydroxyvitamin D

KW - All-trans retinoic acid

KW - Differentiation

KW - Indirubin

KW - Leukemia

UR - http://www.scopus.com/inward/record.url?scp=33747190407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747190407&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2006.05.044

DO - 10.1016/j.bmc.2006.05.044

M3 - Article

C2 - 16765600

AN - SCOPUS:33747190407

VL - 14

SP - 6752

EP - 6758

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 19

ER -